Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study

Completed · Phase 3 · Has a placebo group

Conditions studied: Hypercholesterolemia

In brief

To evaluate the efficacy, safety, and tolerability of 52 weeks of subcutaneous (SC) evolocumab (AMG 145) compared with placebo when added to assigned background lipid-lowering therapy.

Key facts

Study ID
NCT01516879
Run by
Amgen
People needed
905
Starts
2012-01-05
Expected to finish
2013-10-14
Last updated by the study team
2022-07-22

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.